-
TACTI-002 patient recruitment update
-
Three patients now enrolled and dosed in INSIGHT-004, recruitment ongoing
-
Significant eftilagimod alpha clinical data expected in coming months:
-
AIPAC Phase II - first data expected in Q1 calendar year 2020
-
TACTI-002 Phase II - first data in Q3 calendar year 2019
-
TACTI-mel Phase I - final data expected in Q4 calendar year 2019
-
INSIGHT-004 Phase I - initial data expected in Q4 calendar year 2019
-
Equity financing announced in July to raise approximately A$10 million, via a Placement and a fully underwritten Entitlement Offer which will include management team and director participation
SYDNEY, AUSTRALIA – July 26, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),
Eftilagimod alpha (“efti” or “IMP321”) Clinical Update a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product candidates as well as its equity financing, announced 9 July 2019.
For further information please download the attached PDF:
Download this document
